Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
We believe these data underscore the potential of CagriSema to address unmet medical needs in obesity and support long-term disease management." The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomized, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 ) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomized, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 )
-:
Batch-verified research materials free U.S
Support was helpful when I had questions
KLOW works below where topical skincare reaches, on the structural layer where firmness and texture actually live and provides an inflammation control
US$ 23.10
US$ 22.95
US$ 25.46
US$ 26.15
US$ 25.70
US$ 21.35